Latest Blood disorders Stories
Findings could yield therapies against these serious blood diseases and related cancers Researchers at Albert Einstein College of Medicine of Yeshiva University have found that abnormal bone marrow stem cells drive the development of myelodysplastic syndromes (MDS), serious blood diseases that are common among the elderly and that can progress to acute leukemia. The findings could lead to targeted therapies against MDS and prevent MDS-related cancers. "Researchers have suspected that...
WHITE PLAINS, N.Y. and PRINCETON, N.J., July 2, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society® (LLS) and Celator Pharmaceuticals, Inc. today announced a significant expansion of their partnership to support clinical development and potential registration of Celator's lead product candidate CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for treatment of adults with acute myeloid leukemia (AML). Under the new agreement, LLS will provide $5 million in funding,...
Findings Could Yield Therapies Against These Serious Blood Diseases and Related Cancers BRONX, N.Y., July 2, 2012 /PRNewswire-USNewswire/ -- Researchers at Albert Einstein College of Medicine of Yeshiva University have found that abnormal bone marrow stem cells drive the development of myelodysplastic syndromes (MDS), serious blood diseases that are common among the elderly and that can progress to acute leukemia. The findings could lead to targeted therapies against MDS and prevent...
LIVERPOOL, England and NES-ZIONA, Israel, June 29, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that PROLOR scientist Dr. Gili Hart will present data on the company's long-acting clotting factors in preclinical development for the treatment of hemophilia at the 58th Annual Meeting of the Science and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH). Dr. Hart's oral presentation will take place tomorrow, June 30,...
A new cancer drug with remarkably few side effects is dramatically improving survival in Hodgkin lymphoma patients who fail other treatments and are nearly out of options. Loyola University Medical Center oncologist Scott E. Smith, MD, PhD presented survival data for the drug, brentuximab vedotin (Adcetris®), at the 17th Congress of the European Hematology Association. Smith is director of Loyola's Hematological Malignancies Research Program. The multi-center study included 102 Hodgkin...
Trial led by St. Jude Children's Research Hospital investigators succeeds in keeping cure rates high for young patients with favorable-risk Hodgkin lymphoma while reducing their chances of serious treatment side effects A multicenter trial showed that nearly half of young patients with early-stage Hodgkin lymphoma can be cured without undergoing either irradiation or intensive chemotherapy that would leave them at risk for second cancers, infertility, heart and other problems later. St....
WHITE PLAINS, N.Y., June 27, 2012 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) was deeply saddened to learn of the death of the supremely talented Nora Ephron, from acute myelogenous leukemia (AML). Ephron had been battling myelodysplastic syndrome (MDS), which then progressed to AML. MDS is a group of diseases of the blood and bone marrow, with varying degrees of severity. Sometimes MDS can develop as a result of treatment for a different cancer. MDS is often a...
WASHINGTON, June 27, 2012 /PRNewswire-USNewswire/ -- On June 26, 2012, the Senate passed the final Prescription Drug User Fee Act (PDUFA) legislation, (The Food and Drug Administration (FDA) Safety and Innovation Act, S. 3187) including important provisions to mitigate drug shortages, most notably requiring manufacturers to provide advanced notification of stoppages or interruptions in production that could result in a drug shortage. The bill, which was passed by the House on...
WHITE PLAINS, N.Y., June 27, 2012 /PRNewswire/ -- Tap your inner superhero and grab your shield: the inaugural Herothon Half Marathon Series Powered by The Leukemia & Lymphoma Society takes flight this winter! The Leukemia & Lymphoma Society (LLS), which has operated the world's biggest and most successful endurance sports training program, Team In Training (TNT), for the past 24 years, is now spreading its wings with this new endurance series of its own. The Herothon...
Trial led by St. Jude Children's Research Hospital investigators succeeds in keeping cure rates high for young patients with favorable-risk Hodgkin lymphoma while reducing their chances of serious treatment side effects MEMPHIS, Tenn., June 26, 2012 /PRNewswire-USNewswire/ -- A multicenter trial showed that nearly half of young patients with early-stage Hodgkin lymphoma can be cured without undergoing either irradiation or intensive chemotherapy that would leave them at risk for...
